StrixNB(TM) Effective Against Cat Bite Wound Infections
WINNIPEG, MANITOBA--(Marketwired - Mar 11, 2014) - Kane Biotech
Inc. (TSX-VENTURE:KNE), a biotechnology company engaged in the
development and commercialization of products that prevent and
remove microbial biofilms is pleased to announce the results of an
in vitro efficacy study demonstrating that StrixNB oral
care product is effective against cat bite wound infection
associated bacteria.
The World Health Organization estimates in the United States
there are 400,000 cat bites and 66,000 visits to hospital emergency
departments every year. According to a recent study conducted by
Mayo Clinic published in the Journal of Hand Surgery, 1 in 3
patients with cat bite hand wounds had to be hospitalized with
two-third of those hospitalized needing surgery. Pasteurella
multocida and Streptococcus mitis are more frequently
found bacteria in cat bite wounds. Other less frequently found
bacteria include Staphylococcus epidermidis,
Porphyromonas spp. and Fusobacterium
nucleatum.
The most common type of infection is a non-purulent wound with
cellulitis, lymphangitis followed by a purulent wound without
abscess formation and abscesses. A cat bite or scratch can also
transmit some of these pathogens, especially P. multocida,
to humans (zoonotic transmission) and possibly cause soft-tissue
infection, deep-seated abscesses, sepsis, septic arthritis,
peritonitis, pneumonia, meningitis and endocarditis.
The Company tested its unique StrixNB pet oral care formulation
against these pathogens and it was very effective resulting in up
to 100% killing of test organisms. Cats on StrixNB as part of their
oral care treatment may help to reduce the impact of cat bite wound
infections.
About StrixNB™
StrixNB is an effective oral care product helping maintain and
promote good dental and oral hygiene for companion animals. StrixNB
is xylitol-free, made using 100% human food grade ingredients and
registered with the Interim Notification Program of Health Canada
for Low Risk Veterinary Health Products.
StrixNB works against dental disease-associated bacteria by
altering the mouth's environment. It breaks through dental biofilm
- a highly structured, matrix-embedded microbial population -
leaving bacteria otherwise inaccessible exposed for eradication by
a microbial agent.
For more information about our product, please visit our website
at www.strixnb.com or like us on Facebook at
www.facebook.com/StrixNB.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the
development and commercialization of products that prevent and
remove biofilms. Biofilms develop when bacteria and other
microorganisms form a protective matrix that acts as a shield
against attack. When in a biofilm, bacteria become highly resistant
to antibiotics, biocides, disinfectants, high temperatures and host
immune responses. This resiliency contributes to human health
problems such as recurrent urinary tract infections, medical device
associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on
molecular mechanisms of biofilm formation/dispersal and methods for
finding compounds that inhibit or disrupt biofilms. The Company has
evidence that these technologies have potential to significantly
improve the ability to prevent and/or destroy biofilms in several
medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release
constitute forward-looking information within the meaning of
applicable Canadian provincial securities legislation
(collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, including, without limitation, our anticipated future
operating results, and can, in some cases, be identified by the use
of words such as "believe," "anticipate," "expect," "intend,"
"plan," "will," "may" and other similar expressions. In addition,
any statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and
are based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
Kane's early stage of development, lack of product revenues and
history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in Kane's filings with Canadian securities
regulatory authorities, as well as Kane's ability to anticipate and
manage the risks associated with the foregoing. Kane cautions that
the foregoing list of important factors that may affect future
results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.
These risks and uncertainties should be considered carefully
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Kane cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update
or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks
of Kane Biotech Inc. All Rights Reserved 2014
Kane Biotech Inc.Gord FroehlichPresident &
CEO204-477-7592204-474-7552ir@kanebiotech.comwww.kanebiotech.com
Kane Biotech (TSXV:KNE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Kane Biotech (TSXV:KNE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024